EGFR and lung carcinoma: Determining the presence of EGFR mutations is crucial in terms of selecting patients with advanced or metastatic lung cancer who will receive treatments with TKIs, such as gefitinib or erlotinib, because activating mutations in the EGFR gene in lung tumours is associated with an effective and dramatic response to TKIs (6).